You are using an outdated browser. For a faster, safer browsing experience, upgrade for free today.

About Our Products

The status of steroids in the treatment of eye diseases remains unsurpassed. The role of a steroid is to promote barrier function by suppressing the leaking from vessels and suppressing oedema by promoting pump action in the eye as well as promoting homeostasis of the retinal environment. Unlike any other compound, ophthalmic steroids are designed to return physiologically compromised tissue back to balance.

Eye Co is a distinctive early stage Australian company that already has revenues derived from sales of an established product trademarked Vistaplus™ .

The company also sees near term revenue opportunities from early licensing of the new Vistaplus™MR technology; pan-European and Australian patents have been granted, and a new global patent filing for steroid formulations has been finalized. These products are applicable to the treatment of a range of front and back of eye conditions. They are organized into two product portfolios, namely:

Vistaplus™ (triamcinolone acetonide) and
Vistaplus™ MR (mineralocorticoids).

Steroids act through two classes of nuclear receptors, the glucocorticoid receptor (GR) and the mineralocorticoid receptor (MR). Most current steroid ocular treatments have targeted the GR pathway, and it is this pathway that is associated with clinical side effects.

Eye Co's exciting new technology promises to minimise these side effects but maintain clinical efficacy by targeting the alternative MR pathway. When the mineralocorticoid nuclear receptor is activated it triggers a series of events that lead to improvement in ocular cell barrier-function, decreased cell permeability and reduced tissue oedema.


The Vista+™ MC Product Advantage

The early rationale for the injection of intraocular agents (e.g. ranibizumab) was to inhibit growth of new pathological blood vessels...

read more

The Vista+™ Product Advantage

Vista+™ is Eye Co's triamcinolone acetonide formulation. It is uniquely presented in a unit dose syringe providing the treating...

read more

Published Clinical Data

Steroids: role in Diabetic Retinopathy

Steroids: role in Macular Oedema

Steroids: role in Age Related Macular Degeneration